clinical trial · NCT07064018
Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies
University of California, Irvine·phase2·recruiting·n = 67
Soft-tissue SarcomaTriple Negative Breast CancerNon-small Cell Lung CancerCervical CancerOvarian CancerKRAS Mutation-Related TumorsSpedox-6PegfilgrastimFilgrastim
brief summary
This is a Phase 1b/IIa dose escalation clinical trial determining the recommended phase II dose of SPEDOX-6 in subjects with advanced, therapy-refractory soft-tissue sarcoma (STS); triple-negative breast cancer (TNBC); Non-small cell lung cancer (NSCLC); cervical cancer; ovarian cancer; KRAS mutant pancreatic ductal adenocarcinoma. These are subjects who have not previously been treated with anthracyclines.
started
Apr 30, 2025
primary completion
Dec 31, 2029
completion
Dec 31, 2031
last updated
Jul 14, 2025
official title
Phase Ib/IIa Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol